Biology Reference
In-Depth Information
This review suggests that there are major questions about the basic
biology and the epidemiology of
P. vivax
relapse, which need answering,
if we are to address seriously controlling and eliminating this important
malaria parasite (
Garnham, 1966
;
Mendis et al., 2001
).
ACKNOWLEDGEMENTS
NW is a Wellcome Trust Principal Fellow and MI is a Wellcome Trust Intermediate
Fellow.
We are very grateful to our colleagues past and present in the Wellcome-Trust Mahidol
University Oxford Tropical Medicine Research Programme who have contributed to this
research and the development of these concepts.
REFERENCES
Adak, T., Sharma, V.P., Orlov, V.S., 1998. Studies on the
Plasmodium vivax
relapse pattern in
Delhi, India. Am. J. Trop. Med. Hyg. 59, 175-179.
Adak, T., Valecha, N., Sharma, V.P., 2001.
Plasmodium vivax
polymorphism in a clinical drug
trial. Clin. Diagn. Lab. Immunol. 8, 891-894.
Alving, A.S., Craige, B., Jones, R., Whorton, C.M., Pullman, T.N., Eichelberger, L., 1948.
Pentaquine (SN-13,276) a therapeutic agent effective in reducing the relapse rate in
vivax malaria. J. Clin. Invest. 27, 25-33.
Alving, A.S., Arnold, J., Hockwald, R.S., Clayman, C.B., Dern, R.J., Beutler, E., Flanagan, C.L.,
1955. Potentiation of the curative action of primaquine in vivax malaria by quinine and
chloroquine. J. Lab. Clin. Med. 46, 301-306.
Arnold, J., Alving, A.S., Clayman, C.B., 1961. Induced primaquine resistance in vivax malaria.
Trans. R. Soc. Trop. Med. Hyg. 55, 345-350.
Baird, J.K., 2009. Resistance to therapies for infection by
Plasmodium vivax
. Clin. Microbiol.
Rev. 22, 508-534.
Beier, J.C., Davis, J.R., Vaughan, J.A., Noden, B.H., Beier, M.S., 1991. Quantitation of
Plas-
modium falciparum
sporozoites transmitted in vitro by experimentally infected
Anopheles
gambiae
and
Anopheles stephensi
. Am. J. Trop. Med. Hyg. 44, 564-570.
Bianco, A.A., Saunders, G.M., Levine, A.S., Cohn, R.V., 1947. Long term observation of
Plasmodium vivax
malaria. U. S. Naval Med. Bull. 47, 550.
Bignami, A., 1913. Concerning the pathogenesis of relapses in malarial fevers. South. Med.
J. 6, 79-89.
Boyd, M.F., 1940a. On strains or races of the malaria parasites. Am. J. Trop. Med. 20, 69-80.
Boyd, M.F., 1940b. The influence of sporozoite dosage in vivax malaria. Am. J. Trop. Med.
20, 279-286.
Boyd, M.F., 1947. A review of studies on immunity to vivax malaria. J. Natl. Malar. Soc. 6,
12-31.
Boyd, M.F., Kitchen, S.F., 1943. Renewed clinical activity in vivax malaria. Am. J. Trop. Med.
Hyg. 23, 221-234.
Boyd, M.F., Stratman-Thomas, W.K., 1933. A controlled technique for the employment of
naturally induced malaria in the therapy of paresis. Am. J. Hyg. 17, 37-43.
Boyd, M.F., Stratman-Thomas, W.K., Kitchen, S.F., 1936. On the duration of homologous
immunity to
Plasmodium vivax
. Am. J. Trop. Med. 21, s1-s16 311-315.
Brasil, P., de Pina Costa, A., Saraiva Pedro, R., da Silveira Bressan, C., da Silva, S., Tauil, P.L.,
Daniel-Ribeiro, C.T., 2011. Unexpectedly long incubation period of
Plasmodium vivax
malaria, in the absence of chemoprophylaxis, in patients diagnosed outside the transmis-
sion area in Brazil. Malar. J. 10, 122.